Also, double unrelated cord blood transplant tied to better outcomes in leukemia patients
Tuesday, December 7, 2010 (Last Updated: 12/08/2010)
TUESDAY, Dec. 7 (HealthDay News) -- Individuals who donate peripheral blood stem cells (PBSCs) or bone marrow do not appear to be at an overall increased risk of cancer, according to research being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. According to another study, acute myeloid or lymphoblastic leukemia patients who receive double unrelated cord blood transplants may experience better overall outcomes than those who receive single cord blood transplants. Other studies being presented address stem cell transplant procedures in treating various hematologic malignancies and highlight zoledronic acid's ability to improve survival in multiple myeloma patients.
In a retrospective study, Alexander H. Schmidt, M.D., Ph.D., of the DKMS German Bone Marrow Donor Center in Tubingen, and colleagues evaluated whether there were any long-term risks of developing cancer following the donation of PBSCs or bone marrow using a follow-up questionnaire sent to 15,456 donors. Compared to the general population, the investigators found that unrelated PBSC and bone marrow donors did not carry an increased risk of developing cancer.
In another retrospective study, Vanderson Rocha, M.D., Ph.D., of the Hôpital Saint Louis in Paris, and colleagues compared the benefits of double unrelated cord blood transplant versus single cord blood transplant in adults with acute myeloid or lymphoblastic leukemia in remission. At three years, in patients still in first remission, unadjusted cumulative relapse incidence was 15 percent in patients who received a double transplant and 25 percent in those who received a single transplant. The rate of leukemia-free survival was 53 percent in patients who received a double transplant and 39 percent in those who received a single transplant. In addition, 45 percent of those who received a double transplant experienced acute graft-versus-host disease compared with 27 percent following a single transplant.
"Results from this analysis demonstrate that not only is a double cord blood transplant feasible, but the procedure is associated with better overall outcomes, especially when it is used early in the treatment of acute leukemias," Rocha said in a statement.
Hematology & Oncology
Copyright © 2010 HealthDay. All rights reserved.